

## REMARKS

Reconsideration and reexamination is respectfully requested. The indication of allowed subject matter is acknowledged with appreciation.

Claims 1-3 and 41 were rejected under Section 103 as being unpatentable over Edmonds-Alt et al. Claim 1 has been amended to incorporate the subject matter from claim 4. Support for this amendment may be found in the specification, page 50, lines 4-9. No new matter is being added by this amendment. Because of the amendment to claim 1, claims 2, 5, and 28 have also been amended, claim 4, 23, 24, 32 and 34 have been canceled. Therefore, withdrawal of the Section 103 rejection is respectfully requested.


Claims 1-3, 26-30 and 41 were rejected under Section 112, second paragraph. Due to the amendment of claim 1, this rejected is deemed mote. Therefore, withdrawal of the Section 112 rejection is respectfully requested.

Claim 48-50 were withdrawn from consideration as being directed to method of treatment claims. Rejoinder of the claims is respectfully requested. The claims have been amended to depend from allowable compound claims and therefore rejoinder is appropriate. New claims 51-53 are being added by this amendment. Support for these new claims may be found in the original claims 48-50. No new matter is being added by this amendment. Allowance of these claims is respectfully requested.

The application is now believed to be in condition for allowance and notification thereof is respectfully requested. The Examiner is welcomed to call Applicant's representative at the telephone number below if he feels a telephone interview would further prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

  
\_\_\_\_\_  
Mary K. VanAtten  
Attorney for Applicant  
Reg. No. 39,408  
Phone: 609-252-4379  
Date: January 13, 2006